Eligo Bioscience: powering the scale-up of its microbiome engineering platform
Hear, first-hand, how digital transformation is enabling the scale-up of Eligo’s Bioscience microbiome engineering platform. Eligo Bioscience develops first-in-class proprietary modalities that enable the delivery and expression of therapeutic DNA in target bacterial populations of the microbiome. This technology, for the first time, allows the in-situ modulation of the microbiome’s composition and function to address human disease with an unprecedented precision.
Erica Lieberman, Discovery & Automation Team Lead at Eligo Bioscience and Charlotte Hamel, Customer Success Manager at Benchling show how the Benchling R&D Cloud is helping scientists at Eligo centralize data, improve collaboration across teams, make faster decisions, and track end-to end sample management.
